Palvella Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.10 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $132.73Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $1.9B Shares Outstanding 13.9M diluted Next Earnings Date11 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Palvella Therapeutics is a highly promising clinical-stage biopharmaceutical company focused on rare genetic skin diseases and vascular malformations with no FDA-approved therapies. The company's lead candidate, QTORIN 3.9% rapamycin anhydrous gel, has demonstrated outstanding Phase 3 SELVA results in microcystic lymphatic malformations (mLMs), meeting its primary endpoint with high statistical significance. Following a successful pre-NDA meeting with the FDA, Palvella is on track to submit its NDA in 2H 2026, positioning it for a potential first-in-disease commercial launch in 1H 2027. Backed by a robust pro forma cash position of approximately $274 million (following an oversubscribed $230 million financing in early 2026), the company is fully funded to execute its near-term clinical and commercial milestones, making it an attractive investment opportunity in the orphan drug space. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$205.00 Mean target$230.53 High · most bullish analyst$270.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $192.0015% The NDA submission is delayed due to administrative or CMC (chemistry, manufacturing, and controls) hurdles, or the FDA issues a Complete Response Letter (CRL) requesting additional clinical data. Commercial launch is pushed back, increasing the cash burn rate and depressing investor sentiment. Base CaseCentral scenario $230.5360% Matches the consensus meanPalvella successfully submits the NDA for QTORIN rapamycin in 2H 2026. The FDA approves the drug in 1H 2027, and the company initiates a targeted commercial launch in the U.S. Clinical trials for secondary indications progress as planned, and the company maintains a strong cash runway into 2028. Bull CaseUpside scenario $270.0025% The FDA grants priority review and approves QTORIN rapamycin in early 1H 2027 with a broad label. Commercial adoption is rapid due to the lack of approved alternatives and strong support from key opinion leaders. Simultaneously, Phase 2 trials in cutaneous venous malformations and clinically significant angiokeratomas yield highly positive data, expanding the addressable market and driving the stock toward the high end of analyst targets. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |